Detail Information of Genetic Polymorphisms

General Information of Drug Transporter (DT)
DT ID	DTD0010 Transporter Info
Gene Name	SLC22A1
Protein Name	Organic cation transporter 1
Gene ID	6580
UniProt ID	O15245
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs12208357
Site of GPD	chr6:160122116 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0204/102 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total
Metformin	Drug Info	Diabetes Mellitus	Correlated with the increased drug bioavailability (AUC, CL & AUC/CL ratio)	[ 1]
Methadone	N.A.	Discontinuation	Allele C is not associated with increased likelihood of Discontinuation when treated with methadone in people with Opioid-Related Disorders as compared to allele T.	[ 2]
Metformin	N.A.	Pruritus	Allele C is associated with increased bioavailability (AUC, CL & AUC/CL ratio) when exposed to metformin.	[ 1]
Allele T	Click to Show/Hide the Full List of Affected Drugs: 22 Drugs in Total
Tramadol	Drug Info	Healthy Individuals	Correlated with the higher o-desmethyltramadol plasma concentrations in healthy individuals (compare with allele C)	[ 3]
Metformin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with allele C)	[ 4]
Metformin	Drug Info	Diabetes Mellitus	Irrelevant to the drug response in patients (compare with allele C)	[ 5]
Metformin	Drug Info	Polycystic Ovary Syndrome	Irrelevant to the drug response in patients (compare with allele C)	[ 6]
Proguanil	N.A.	Discontinuation	Allele T is associated with decreased uptake of proguanil as compared to allele C.	[ 7]
Antiemetics And Antinauseants	N.A.	Neutropenia	Allele T is associated with decreased response to Antiemetics And Antinauseants as compared to allele C.	[ 8]
Ranitidine	N.A.	Neutropenia	Allele T is associated with decreased transport of ranitidine as compared to allele C.	[ 9]
Sulfonamides, Urea Derivatives	N.A.	Hypoventilation	Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	[ 10]
Metformin	N.A.	Overall Survival	Allele T is associated with increased exposure to metformin in healthy individuals as compared to allele C.	[ 4]
Sumatriptan	N.A.	Overall Survival	Allele T (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele C (assigned as high activity phenotype) .	[ 11]
Fenoterol	N.A.	Overall Survival	Allele T are associated with increased exposure to fenoterol in healthy individuals as compared to allele C.	[ 12]
Cycloguanil	N.A.	Overall Survival	Allele T are associated with increased concentrations of cycloguanil in healthy individuals as compared to allele C.	[ 7]
O-desmethyltramadol	N.A.	Overall Survival	Allele T is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele C.	[ 13]
Tramadol	N.A.	Overall Survival	Allele T is associated with decreased dose of tramadol in people with Pain as compared to allele C.	[ 13]
Morphine	N.A.	Postoperative Nausea And Vomiting	Allele T is associated with increased likelihood of Postoperative Nausea and Vomiting when treated with morphine in children as compared to allele C.	[ 14]
Morphine	N.A.	Death	Allele T is not associated with dose of morphine in people with Pain, Postoperative as compared to allele C.	[ 15]
Metformin	N.A.	Event-free Survival	Allele T is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	[ 5]
Morphine	N.A.	Nausea	Allele T is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele C.	[ 15]
Morphine	N.A.	Pruritus	Allele T is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele C.	[ 15]
Metformin	N.A.	Pruritus	Allele T is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele C.	[ 6]
Fenoterol	N.A.	Adverse Events	Allele T are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele C.	[ 12]
Tramadol	N.A.	Drug Toxicity	Allele T is associated with higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to allele C.	[ 3]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs: 6 Drugs in Total
Metformin	Drug Info	Healthy Individuals	Correlated with the decreased drug exposure in healthy individuals (compare with genotype CC)	[ 16]
Valganciclovir	N.A.	Neutropenia	Genotype TT is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.	[ 17]
Morphine	N.A.	Overall Survival	Genotype TT is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes CC + CT.	[ 18]
Metformin	N.A.	Pruritus	Genotype TT is associated with decreased exposure to metformin in healthy individuals as compared to genotype CC.	[ 16]
Metformin	N.A.	Gastrointestinal Stromal Tumors	Patients with the TT genotype who are treated with metformin may have decreased bioavailability of metformin as compared to patients with the CC or CT genotypes, however the opposite is reported in one study, and no association was reported in two studies . Other clinical and genetic factors may also influence bioavailability of metformin.	[ 1]
Tramadol	N.A.	Diabetes Mellitus, Type 2	Patients with the rs12208357 TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.	[ 3]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total
Rasagiline	N.A.	Neutropenia	Genotype CT is associated with decreased clearance of rasagiline in healthy individuals as compared to genotype CC.	[ 19]
Valganciclovir	N.A.	Neutropenia	Genotype CT is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.	[ 17]
Metformin	N.A.	Gastrointestinal Stromal Tumors	Patients with the CT genotype and who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotype, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.	[ 1]
Tramadol	N.A.	Diabetes Mellitus, Type 2	Patients with the rs12208357 CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.	[ 3]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Morphine	N.A.	Pruritus	Genotypes CT + TT is associated with decreased clearance of morphine in children as compared to genotype CC.	[ 20]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Metformin	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotypes, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.	[ 1]
Tramadol	N.A.	Diabetes Mellitus, Type 2	Patients with the rs12208357 CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.	[ 3]
Genetic Polymorphism	rs2282143
Site of GPD	chr6:160136611 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	T=0.0663/332 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total
Metformin	Drug Info	Healthy Individuals	Correlated with the increased drug clearance in healthy individuals (compare with Genotypes CT + TT)	[ 21]
Metformin	N.A.	Hypoventilation	Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotypes CT + TT.	[ 21]
Lamotrigine	N.A.	Eye Diseases	Genotype CC is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype CT.	[ 22]
Imatinib	N.A.	Drug Toxicity	Genotype CC is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	[ 23]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Proguanil	N.A.	Eye Diseases	Genotype CT is associated with increased exposure to proguanil in healthy individuals as compared to genotype CC.	[ 24]
Metformin	N.A.	Diabetes Mellitus	Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.	[ 21]
Allele C	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Lamotrigine	N.A.	Eye Diseases	Allele C is not associated with response to lamotrigine in people with Epilepsy as compared to allele T.	[ 22]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus	Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.	[ 21]
Genetic Polymorphism	rs35167514
Site of GPD	chr6:160139849 (GRCh38.p12)
GPD Type	DeletionDeletion
Allele(s) in dbSNP	delA
Genotype DEL	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Tramadol	Drug Info	Healthy Individuals	Correlated with the increased plasma concentrations of o-desmethyltramadol in healthy individuals (compare with allele A)	[ 3]
Genotype del	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Antiemetics And Antinauseants	N.A.	Discontinuation	Allele del is associated with decreased response to Antiemetics And Antinauseants as compared to allele A.	[ 8]
Tramadol	N.A.	Drug Toxicity	Allele del is associated with increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to allele A.	[ 3]
Genotype A/del	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Tramadol	N.A.	Recurrence	Patients with the A/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.	[ 3]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Tramadol	N.A.	Recurrence	Patients with the AA genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the del/del genotype. Other genetic or clinical factors may also influence the clearance of tramadol.	[ 3]
Genotype del/del	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Tramadol	N.A.	Recurrence	Patients with the del/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.	[ 3]
Genetic Polymorphism	rs36056065
Allele GTAAGTTG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	Drug Info	Diabetes Mellitus	Correlated with the gastrointestinal side effects in patients (compare with allele del)	[ 25]
Genotype del	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Methadone	N.A.	Discontinuation	Allele del is not associated with increased likelihood of Discontinuation when treated with methadone in people with Opioid-Related Disorders as compared to allele GTAAGTTG.	[ 2]
Genotype GTAAGTTG	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Metformin	N.A.	Neutropenia	Allele GTAAGTTG is associated with gastrointestinal side effects when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele del.	[ 25]
Metformin	N.A.	Diabetes Mellitus, Type 2	Allele GTAAGTTG is associated with gastrointestinal side effects when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele del.	[ 25]
Genotype GTAAGTTG/GTAAGTTG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the GTAAGTTG/GTAAGTTG genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 25]
Genotype GTAAGTTG/del	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the GTAAGTTG/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype or may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 25]
Genotype del/del	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the del/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 25]
Genetic Polymorphism	rs628031
Site of GPD	chr6:160139813 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.3123/1564 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs: 19 Drugs in Total
Metformin	Drug Info	Diabetes Mellitus	Correlated with the decreased drug response in patients (compare with allele G); Correlated with the gastrointestinal toxicity in patients (compare with allele G)	[ 25], [ 27]
Lamotrigine	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with Allele G)	[ 22]
Metformin	N.A.	Gastrointestinal Toxicity	Allele A is associated with gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	[ 25]
Efavirenz	N.A.	Hypoventilation	Allele A is not associated with increased resistance to efavirenz, lamivudine, lopinavir, nevirapine, ritonavir and zidovudine in people with HIV Infections as compared to allele G.	[ 29]
Lamivudine	N.A.	Hypoventilation	Allele A is not associated with increased resistance to efavirenz, lamivudine, lopinavir, nevirapine, ritonavir and zidovudine in people with HIV Infections as compared to allele G.	[ 29]
Lopinavir	N.A.	Hypoventilation	Allele A is not associated with increased resistance to efavirenz, lamivudine, lopinavir, nevirapine, ritonavir and zidovudine in people with HIV Infections as compared to allele G.	[ 29]
Nevirapine	N.A.	Hypoventilation	Allele A is not associated with increased resistance to efavirenz, lamivudine, lopinavir, nevirapine, ritonavir and zidovudine in people with HIV Infections as compared to allele G.	[ 29]
Ritonavir	N.A.	Hypoventilation	Allele A is not associated with increased resistance to efavirenz, lamivudine, lopinavir, nevirapine, ritonavir and zidovudine in people with HIV Infections as compared to allele G.	[ 29]
Zidovudine	N.A.	Hypoventilation	Allele A is not associated with increased resistance to efavirenz, lamivudine, lopinavir, nevirapine, ritonavir and zidovudine in people with HIV Infections as compared to allele G.	[ 29]
Metformin	N.A.	Overall Survival	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	[ 27]
Metformin	N.A.	Overall Survival	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	[ 30]
Imatinib	N.A.	Pruritus	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 31]
Imatinib	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 31]
Imatinib	N.A.	Discontinuation	Allele A is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 31]
Lamotrigine	N.A.	Eye Diseases	Allele A is not associated with response to lamotrigine in people with Epilepsy as compared to allele G.	[ 22]
Imatinib	N.A.	Neoplasms	Allele A is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 31]
Metformin	N.A.	Diabetes Mellitus, Type 2	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	[ 27]
Metformin	N.A.	Diabetes Mellitus, Type 2	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	[ 30]
Metformin	N.A.	Diabetes Mellitus, Type 2	Allele A is associated with gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	[ 25]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs: 13 Drugs in Total
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug dose in patients (compare with genotypes AA + AG)	[ 30]
Valganciclovir	N.A.	Neutropenia	Genotype GG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype AA.	[ 17]
Imatinib	N.A.	Event-free Survival	Genotype GG is associated with decreased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	[ 32]
Lamotrigine	N.A.	Pruritus	Genotype GG is associated with increased dose of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.	[ 30]
Metformin	N.A.	Drug Toxicity	Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.	[ 33]
Imatinib	N.A.	Drug Toxicity	Genotype GG is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.	[ 34]
Imatinib	N.A.	Neoplasms	Genotype GG is associated with decreased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	[ 32]
Imatinib	N.A.	Neoplasms	Genotype GG is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.	[ 34]
Imatinib	N.A.	Neoplasms	Patients with the GG genotype and cancer may have decreased clearance of imatinib, as well as an increased response and an increased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.	[ 29]
Lamotrigine	N.A.	Epilepsy	Patients with the rs628031 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.	[ 36]
Metformin	N.A.	Diabetes Mellitus, Type 2	Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.	[ 33]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with type II diabetes and the rs628031 GG genotype may be at a decreased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.	[ 25]
Metformin	N.A.	Gastrointestinal Toxicity	Patients with type II diabetes and the rs628031 GG genotype may be at a decreased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.	[ 25]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs: 8 Drugs in Total
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotype GG)	[ 22]
Imatinib	N.A.	Overall Survival	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	[ 36]
Metformin	N.A.	Overall Survival	Genotypes AA + AG is associated with increased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	[ 37]
Metformin	N.A.	Gastrointestinal Toxicity	Genotypes AA + AG is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	[ 38]
Sulfonamides, Urea Derivatives	N.A.	Gastrointestinal Toxicity	Genotypes AA + AG is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	[ 38]
Lamotrigine	N.A.	Eye Diseases	Genotypes AA + AG is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	[ 22]
Imatinib	N.A.	Neoplasms	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	[ 36]
Lamotrigine	N.A.	Epilepsy	Genotypes AA + AG is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	[ 22]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs: 6 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotype AG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype GG.	[ 17]
Imatinib	N.A.	Neoplasms	Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.	[ 29]
Lamotrigine	N.A.	Epilepsy	Patients with the rs628031 AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.	[ 34]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with type II diabetes and the rs628031 AG genotype may have a decreased response to metformin as compared to patients with the GG genotype but an increased response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 32]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with type II diabetes and the rs628031 AG genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.	[ 25]
Metformin	N.A.	Gastrointestinal Toxicity	Patients with type II diabetes and the rs628031 AG genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.	[ 25]
Allele G	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Lamotrigine	N.A.	Eye Diseases	Allele G is not associated with dose of lamotrigine in people with Epilepsy as compared to allele A.	[ 34]
Lamotrigine	N.A.	Epilepsy	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.	[ 34]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs: 5 Drugs in Total
Imatinib	N.A.	Neoplasms	Patients with the AA genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.	[ 29]
Lamotrigine	N.A.	Epilepsy	Patients with the rs628031 AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.	[ 34]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with type II diabetes and the rs628031 AA genotype may have a decreased response to metformin as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 32]
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with type II diabetes and the rs628031 AA genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.	[ 25]
Metformin	N.A.	Gastrointestinal Toxicity	Patients with type II diabetes and the rs628031 AA genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.	[ 25]
Genetic Polymorphism	rs683369
Site of GPD	chr6:160130172 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.1238/620 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs: 7 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the decreased drug concentrations in patients (compare with genotypes CG + GG); Correlated with the increased drug clearance in patients (compare with genotypes CG + GG)	[ 38]
Imatinib	N.A.	Neutropenia	Genotype CC is associated with decreased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CG + GG.	[ 39]
Imatinib	N.A.	Overall Survival	Genotype CC is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	[ 40]
Imatinib	N.A.	Pruritus	Genotype CC is associated with increased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	[ 38]
Imatinib	N.A.	Drug Toxicity	Genotype CC is associated with decreased severity of Drug Toxicity when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	[ 40]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.	[ 41]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype CC is associated with increased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	[ 38]
Genotypes CG + GG	Click to Show/Hide the Full List of Affected Drugs: 9 Drugs in Total
Imatinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the increased conjunctival hemorrhage risk in patients (compare with genotype CC)	[ 41]
Nilotinib	N.A.	Event-free Survival	Genotypes CG + GG is not associated with likelihood of event-free survival when treated with nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.	[ 43]
Imatinib	N.A.	Hypoventilation	Genotypes CG + GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.	[ 35]
Cisplatin	N.A.	Overall Survival	Genotypes CG + GG is associated with increased overall survival when treated with cisplatin in people with Esophageal Neoplasms as compared to genotype CC.	[ 45]
Imatinib	N.A.	Event-free Survival	Genotypes CG + GG is associated with decreased event-free survival when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.	[ 38]
Imatinib	N.A.	Drug Toxicity	Genotypes CG + GG is associated with increased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	[ 41]
Imatinib	N.A.	Eye Diseases	Genotypes CG + GG is associated with increased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	[ 41]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotypes CG + GG is associated with increased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	[ 41]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotypes CG + GG is associated with decreased event-free survival when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.	[ 38]
Allele G	Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total
Imatinib	N.A.	Pruritus	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	[ 29]
Imatinib	N.A.	Drug Toxicity	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	[ 29]
Imatinib	N.A.	Discontinuation	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.	[ 29]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.	[ 41]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.	[ 38]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.	[ 41]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the GG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.	[ 38]
Genetic Polymorphism	rs72552763
Site of GPD	chr6:160139849-160139853 (GRCh38.p12)
GPD Type	Indel Insertion and Deletion
Allele(s) in dbSNP	delGAT
Genotype GAT/DEL	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Metformin	Drug Info	Diabetes Mellitus	Correlated with the decreased drug trough steady-state concentration in patients (compare with genotype GAt/GAt)	[ 44]
Metformin	N.A.	Diabetes Mellitus	Patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 44]
Genotype del	Click to Show/Hide the Full List of Affected Drugs: 10 Drugs in Total
Ranitidine	N.A.	Hypersensitivity	Allele del is associated with decreased transport of ranitidine as compared to allele GAT.	[ 9]
Mercaptopurine	N.A.	Infectious Disease	Allele del is associated with increased severity of Infection when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele GAT.	[ 46]
Morphine	N.A.	Nausea	Allele del is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele GAT.	[ 15]
Morphine	N.A.	Pruritus	Allele del is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele GAT.	[ 15]
Morphine	N.A.	Pruritus	Allele del is not associated with dose of morphine in people with Pain, Postoperative as compared to allele GAT.	[ 15]
Sulfonamides, Urea Derivatives	N.A.	Neutropenia	Allele del is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele GAT.	[ 10]
Metformin	N.A.	Neutropenia	Allele del is not associated with exposure to metformin as compared to allele GAT.	[ 4]
Metformin	N.A.	Neutropenia	Allele del is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele GAT.	[ 5]
Metformin	N.A.	Neutropenia	Allele del is not associated with CLrenal nor the secretory clearance (CLsec) of metformin when exposed to metformin in healthy individuals as compared to allele GAT.	[ 51]
Proguanil	N.A.	Neutropenia	Allele del is associated with decreased uptake of proguanil as compared to allele GAT.	[ 7]
Genotype del/del	Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total
Metformin	N.A.	Neutropenia	Genotype del/del is associated with decreased exposure to metformin in healthy individuals as compared to genotype GAT/GAT.	[ 16]
Morphine	N.A.	Neutropenia	Genotype del/del is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes GAT/GAT + GAT/del.	[ 18]
Morphine	N.A.	Hypoventilation	Genotype del/del is associated with increased likelihood of Hypoventilation when treated with morphine in children as compared to genotypes GAT/GAT + GAT/del.	[ 14]
Metformin	N.A.	Diabetes Mellitus	Patients with the del/del genotype were not studied but patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 44]
Genotypes GAT/del + del/del	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Morphine	N.A.	Neutropenia	Genotypes GAT/del + del/del is associated with decreased clearance of morphine in children as compared to genotype GAT/GAT.	[ 20]
Genotype GAT/del	Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total
Metformin	N.A.	Neutropenia	Genotype GAT/del is associated with decreased trough metformin steady-state concentration when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.	[ 44]
Metformin	N.A.	Gastrointestinal Toxicity	Genotype GAT/del is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.	[ 37]
Sulfonamides, Urea Derivatives	N.A.	Gastrointestinal Toxicity	Genotype GAT/del is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.	[ 37]
Genotype GAT	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Neutropenia	Allele GAT is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele del.	[ 6]
Genotype GAT/GAT	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus	Patients with the GAT/GAT genotype who are treated with metformin may have an increased trough metformin steady-state concentration as compared to patients with the GAT/DEL genotype. Other genetic and clinical factors may also influence a patient's response to metformin.	[ 44]
Genetic Polymorphism	rs594709
Site of GPD	chr6:160134722 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.3179/1592 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total
Metformin	Drug Info	Diabetes Mellitus	Correlated with the increased drug response in patients (compare with genotype GG)	[ 47]
Metformin	N.A.	Pruritus	Genotypes AA + AG are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	[ 47]
Metformin	N.A.	Diabetes Mellitus, Type 2	Genotypes AA + AG are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	[ 47]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the AA genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.	[ 47]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.	[ 47]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Diabetes Mellitus, Type 2	Patients with the GG genotype and Type 2 Diabetes may have decreased response to metformin compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affects response to metformin.	[ 47]
Genetic Polymorphism	rs55918055
Site of GPD	chr6:160122197 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.9990/1977 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs: 8 Drugs in Total
Ranitidine	N.A.	Hypersensitivity	Allele C is associated with decreased transport of ranitidine as compared to allele T.	[ 9]
Antiemetics And Antinauseants	N.A.	Neutropenia	Allele C is associated with decreased response to Antiemetics And Antinauseants as compared to allele T.	[ 8]
Proguanil	N.A.	Neutropenia	Allele C is associated with decreased uptake of proguanil as compared to allele T.	[ 7]
Fenoterol	N.A.	Overall Survival	Allele C are associated with increased exposure to fenoterol in healthy individuals as compared to allele T.	[ 12]
Sumatriptan	N.A.	Overall Survival	Allele C (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele T (assigned as high activity phenotype) .	[ 11]
O-desmethyltramadol	N.A.	Overall Survival	Allele C is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele T.	[ 13]
Tramadol	N.A.	Overall Survival	Allele C is associated with decreased dose of tramadol in people with Pain as compared to allele T.	[ 13]
Fenoterol	N.A.	Adverse Events	Allele C are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele T.	[ 12]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Morphine	N.A.	Pruritus	Genotypes CC + CT is associated with decreased clearance of morphine in children as compared to genotype TT.	[ 20]
Genetic Polymorphism	rs34059508
Site of GPD	chr6:160154805 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9940/1967 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs: 14 Drugs in Total
Ranitidine	N.A.	Hypersensitivity	Allele A is associated with decreased transport of ranitidine as compared to allele G.	[ 9]
Proguanil	N.A.	Vomiting	Allele A is associated with decreased uptake of proguanil as compared to allele G.	[ 7]
Antiemetics And Antinauseants	N.A.	Neutropenia	Allele A is associated with decreased response to Antiemetics And Antinauseants as compared to allele G.	[ 8]
Metformin	N.A.	Overall Survival	Allele A is not associated with CLrenal nor the secretory clearance (CLsec) of metformin when exposed to metformin in healthy individuals as compared to allele G.	[ 46]
Metformin	N.A.	Overall Survival	Allele A is not associated with exposure to metformin as compared to allele G.	[ 4]
Sumatriptan	N.A.	Overall Survival	Allele A (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele G (assigned as high activity phenotype) .	[ 11]
Fenoterol	N.A.	Overall Survival	Allele A are associated with increased exposure to fenoterol in healthy individuals as compared to allele G.	[ 12]
Tramadol	N.A.	Overall Survival	Allele A is associated with decreased dose of tramadol in people with Pain as compared to allele G.	[ 13]
O-desmethyltramadol	N.A.	Overall Survival	Allele A is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele G.	[ 13]
Morphine	N.A.	Death	Allele A is not associated with exposure to morphine in people with Pain, Postoperative as compared to allele G.	[ 15]
Morphine	N.A.	Nausea	Allele A is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele G.	[ 15]
Morphine	N.A.	Pruritus	Allele A is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele G.	[ 15]
Metformin	N.A.	Pruritus	Allele A is associated with increased bioavailability when exposed to metformin.	[ 1]
Fenoterol	N.A.	Adverse Events	Allele A are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele G.	[ 12]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs: 7 Drugs in Total
Rasagiline	N.A.	Neutropenia	Genotype AG is associated with increased clearance of rasagiline in healthy individuals as compared to genotype GG.	[ 19]
Valganciclovir	N.A.	Neutropenia	Genotype AG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype GG.	[ 17]
Hydrochlorothiazide	N.A.	Neutropenia	Genotype AG is associated with increased dose-adjusted trough concentrations of hydrochlorothiazide null olmesartan in healthy individuals as compared to genotype GG.	[ 50]
Olmesartan	N.A.	Neutropenia	Genotype AG is associated with increased dose-adjusted trough concentrations of hydrochlorothiazide null olmesartan in healthy individuals as compared to genotype GG.	[ 50]
Hydrochlorothiazide	N.A.	Dizziness	Genotype AG is associated with increased likelihood of Dizziness when treated with hydrochlorothiazide and olmesartan in healthy individuals as compared to genotype GG.	[ 50]
Olmesartan	N.A.	Dizziness	Genotype AG is associated with increased likelihood of Dizziness when treated with hydrochlorothiazide and olmesartan in healthy individuals as compared to genotype GG.	[ 50]
Olanzapine	N.A.	Drug Toxicity	Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	[ 51]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Morphine	N.A.	Overall Survival	Genotypes AA + AG is associated with decreased clearance of morphine in children as compared to genotype GG.	[ 20]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Morphine	N.A.	Overall Survival	Genotype AA is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes AG + GG.	[ 18]
Olanzapine	N.A.	Recurrence	There is currently no available evidence regarding the association between the rs34059508 AA genotype and exposure to olanzapine. However, patients with the AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.	[ 49]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Olanzapine	N.A.	Recurrence	Patients with the rs34059508 GG genotype may have decreased exposure to olanzapine as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.	[ 49]
Genetic Polymorphism	rs34130495
Site of GPD	chr6:160139792 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9940/1967 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs: 13 Drugs in Total
Antiemetics And Antinauseants	N.A.	Discontinuation	Allele A is associated with decreased response to Antiemetics And Antinauseants as compared to allele G.	[ 8]
Proguanil	N.A.	Neutropenia	Allele A is associated with decreased uptake of proguanil as compared to allele G.	[ 7]
Ranitidine	N.A.	Neutropenia	Allele A is associated with decreased transport of ranitidine as compared to allele G.	[ 9]
Fenoterol	N.A.	Overall Survival	Allele A are associated with increased exposure to fenoterol in healthy individuals as compared to allele G.	[ 12]
Sumatriptan	N.A.	Overall Survival	Allele A (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele G (assigned as high activity phenotype) .	[ 11]
Cycloguanil	N.A.	Overall Survival	Allele A are associated with increased concentrations of cycloguanil in healthy individuals as compared to allele G.	[ 7]
O-desmethyltramadol	N.A.	Overall Survival	Allele A is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele G (assigned as low activity phenotype) .	[ 13]
Tramadol	N.A.	Overall Survival	Allele A is associated with decreased dose of tramadol in people with Pain as compared to allele G.	[ 13]
Morphine	N.A.	Nausea	Allele A is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele G.	[ 15]
Morphine	N.A.	Pruritus	Allele A is not associated with severity of Nausea or Pruritus when treated with morphine in people with Pain, Postoperative as compared to allele G.	[ 15]
Fenoterol	N.A.	Adverse Events	Allele A are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele G.	[ 12]
Morphine	N.A.	Eye Diseases	Allele A is not associated with dose of morphine in people with Pain, Postoperative as compared to allele G.	[ 15]
Tramadol	N.A.	Drug Toxicity	Allele A is associated with increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals.	[ 3]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Morphine	N.A.	Overall Survival	Genotype AA is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes AG + GG.	[ 18]
Tramadol	N.A.	Neoplasms	Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.	[ 3]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Morphine	N.A.	Pruritus	Genotypes AA + AG is associated with decreased clearance of morphine in children as compared to genotype GG.	[ 20]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
O-desmethyltramadol	N.A.	Pruritus	Genotype GG is associated with decreased concentrations of o-desmethyltramadol in people with Death as compared to genotype AG.	[ 50]
Tramadol	N.A.	Neoplasms	Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.	[ 3]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Tramadol	N.A.	Neoplasms	Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.	[ 3]
Genetic Polymorphism	rs6935207
Site of GPD	chr6:160120141 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.6500/1286 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs: 8 Drugs in Total
Tropisetron	N.A.	Vomiting	Allele A is not associated with likelihood of Vomiting when treated with tropisetron in people with Neoplasms as compared to allele G.	[ 51]
Metformin	N.A.	Overall Survival	Allele A is not associated with clearance of metformin in healthy individuals as compared to allele G.	[ 51]
Cycloguanil	N.A.	Overall Survival	Allele A is not associated with exposure to cycloguanil, fenoterol or sumatriptan in healthy individuals as compared to allele G.	[ 51]
Fenoterol	N.A.	Overall Survival	Allele A is not associated with exposure to cycloguanil, fenoterol or sumatriptan in healthy individuals as compared to allele G.	[ 51]
Sumatriptan	N.A.	Overall Survival	Allele A is not associated with exposure to cycloguanil, fenoterol or sumatriptan in healthy individuals as compared to allele G.	[ 51]
Imatinib	N.A.	Pruritus	Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 29]
Imatinib	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 29]
Imatinib	N.A.	Discontinuation	Allele A is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	[ 29]
Genetic Polymorphism	rs1867351
Site of GPD	chr6:160122091 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.7210/1426 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total
Imatinib	N.A.	Periorbital Edema	Genotype TT is associated with increased likelihood of periorbital edema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	[ 39]
N-desmethyltramadol	N.A.	Pruritus	Genotype TT is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotypes CC + CT.	[ 50]
O-desmethyltramadol	N.A.	Pruritus	Genotype TT is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotypes CC + CT.	[ 50]
Allele C	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Overall Survival	Allele C is not associated with exposure to metformin as compared to allele T.	[ 4]
Genetic Polymorphism	rs1349294037
Site of GPD	chr6:160139877 (GRCh38.p12)
GPD Type	Deletion
Genotype TAAGTTGT/TAAGTTGT	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Sumatriptan	N.A.	Gastrointestinal Toxicity	Genotype TAAGTTGT/TAAGTTGT is associated with increased concentrations of sumatriptan as compared to genotype del/del.	[ 52]
Fenoterol	N.A.	Gastrointestinal Toxicity	Genotype TAAGTTGT/TAAGTTGT is not associated with increased concentrations of fenoterol as compared to genotype del/del.	[ 52]
Genetic Polymorphism	rs41267797
Site of GPD	chr6:160155979 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9330/1846 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
N-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Genotype AG is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype GG.	[ 50]
O-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Genotype AG is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype GG.	[ 50]
Genetic Polymorphism	rs35235578
Site of GPD	chr6:160136672 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9810/1941 (Global)
Genotype CT	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
N-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Genotype CT is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CC.	[ 50]
O-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Genotype CT is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CC.	[ 50]
Genetic Polymorphism	rs9457841
Site of GPD	chr6:160129897 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.5620/1112 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
N-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Allele C is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to allele T.	[ 50]
O-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Allele C is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to allele T.	[ 50]
Genetic Polymorphism	rs34134157
Site of GPD	chr6:160132274 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9860/1951 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
N-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Genotype CC is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CT.	[ 50]
O-desmethyltramadol	N.A.	Gastrointestinal Toxicity	Genotype CC is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CT.	[ 50]
Genetic Polymorphism	rs622342
Site of GPD	chr6:160151834 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G
Minor Allele Frequency	C=0.2650/524 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs: 9 Drugs in Total
Metformin	N.A.	Overall Survival	Genotype AA is not associated with response to metformin in people with genetic variation at rs2289669.	[ 53]
Metformin	N.A.	Overall Survival	Genotype AA is associated with decreased CL renal reference and lower and CL sec reference when exposed to metformin in healthy individuals as compared to genotype CC.	[ 46]
Metformin	N.A.	Diabetes Mellitus	Genotype AA is not associated with response to metformin in people with genetic variation at rs2289669.	[ 53]
Metformin	N.A.	Diabetes Mellitus	Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.	[ 55]
Amantadine	N.A.	Parkinson Disease	Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 56]
Anticholinergics	N.A.	Parkinson Disease	Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 56]
Dopamine Agonists	N.A.	Parkinson Disease	Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 56]
Levodopa	N.A.	Parkinson Disease	Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 56]
Selegiline	N.A.	Parkinson Disease	Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 56]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs: 9 Drugs in Total
Metformin	N.A.	Overall Survival	Genotype AC is associated with response to metformin in people with genetic variation at rs2289669.	[ 53]
Metformin	N.A.	Eye Diseases	Genotype AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + CC.	[ 57]
Metformin	N.A.	Diabetes Mellitus	Genotype AC is associated with response to metformin in people with genetic variation at rs2289669.	[ 53]
Metformin	N.A.	Diabetes Mellitus	Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.	[ 54]
Amantadine	N.A.	Parkinson Disease	Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Anticholinergics	N.A.	Parkinson Disease	Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Dopamine Agonists	N.A.	Parkinson Disease	Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Levodopa	N.A.	Parkinson Disease	Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Selegiline	N.A.	Parkinson Disease	Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs: 8 Drugs in Total
Metformin	N.A.	Overall Survival	Genotype CC is associated with response to metformin in people with genetic variation at rs2289669.	[ 53]
Metformin	N.A.	Diabetes Mellitus	Genotype CC is associated with response to metformin in people with genetic variation at rs2289669.	[ 53]
Metformin	N.A.	Diabetes Mellitus	Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment.	[ 54]
Amantadine	N.A.	Parkinson Disease	Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Anticholinergics	N.A.	Parkinson Disease	Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Dopamine Agonists	N.A.	Parkinson Disease	Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Levodopa	N.A.	Parkinson Disease	Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Selegiline	N.A.	Parkinson Disease	Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.	[ 55]
Allele A	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Metformin	N.A.	Overall Survival	Allele A is not associated with exposure to metformin as compared to allele C.	[ 4]
Metformin	N.A.	Death	Allele A is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele C.	[ 58]
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total
Metformin	N.A.	Overall Survival	Genotypes AC + CC is associated with increased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	[ 36]
Metformin	N.A.	Pruritus	Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	[ 59]
Allele C	Click to Show/Hide the Full List of Affected Drugs: 17 Drugs in Total
Amantadine	N.A.	Death	Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Anticholinergics	N.A.	Death	Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Dopamine Agonists	N.A.	Death	Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Levodopa	N.A.	Death	Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Selegiline	N.A.	Death	Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Metformin	N.A.	Event-free Survival	Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	[ 5]
Amantadine	N.A.	Pruritus	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Anticholinergics	N.A.	Pruritus	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Levodopa	N.A.	Pruritus	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Selegiline	N.A.	Pruritus	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Metformin	N.A.	Pruritus	Allele C is associated with decreased reduction in HbA1c levels when treated with metformin in people with Diabetes Mellitus.	[ 54]
Metformin	N.A.	Diabetes Mellitus	Allele C is associated with decreased reduction in HbA1c levels when treated with metformin in people with Diabetes Mellitus.	[ 54]
Amantadine	N.A.	Parkinson Disease	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Anticholinergics	N.A.	Parkinson Disease	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Dopamine Agonists	N.A.	Parkinson Disease	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Levodopa	N.A.	Parkinson Disease	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Selegiline	N.A.	Parkinson Disease	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	[ 55]
Genetic Polymorphism	rs461473
Site of GPD	chr6:160122530 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9620/1903 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total
Metformin	N.A.	Overall Survival	Allele A is not associated with CLrenal nor the secretory clearance (CLsec) of metformin when exposed to metformin in healthy individuals as compared to allele G.	[ 46]
References
1	Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008 Feb;83(2):273-80.
2	ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundam Clin Pharmacol. 2025 Jun;39(3):e70013.
3	Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011 Jul;90(1):143-50.
4	Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort. Br J Clin Pharmacol. 2018 May;84(5):987-996.
5	Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. Clin Pharmacol Ther. 2017 Jun;101(6):763-772.
6	The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):239-244.
7	OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil. Clin Pharmacol Ther. 2019 Jan;105(1):190-200.
8	Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2012 Feb;12(1):22-9.
9	Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS One. 2017;12(12):e0189521.
10	Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus. Front Pharmacol. 2018 Apr 6;9:320.
11	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
12	Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency. Clin Pharmacol Ther. 2018 May;103(5):868-878.
13	Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain. 2016 Nov;157(11):2467-2475.
14	OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. Pharmacogenomics. 2017 May;18(7):621-629.
15	No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients. Basic Clin Pharmacol Toxicol. 2022 Jan;130(1):93-102.
16	Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans. Clin Pharmacol Ther. 2017 Nov;102(5):841-848.
17	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
18	OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics. 2013 Jul;14(10):1141-51.
19	Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline. Pharmaceutics. 2022 Sep 21;14(10).
20	Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. Clin Pharmacol Ther. 2019 Mar;105(3):761-768.
21	Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J. 2013 Apr;15(2):571-80.
22	Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016 Nov;127:186-190.
23	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013 Feb;98(2):193-200.
24	Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach. Clin Transl Sci. 2024 Dec;17(12):e70103.
25	Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012 Sep;22(9):659-66.
26	Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52(2):117-22.
27	ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J Clin Pharmacol. 2013 Dec;53(12):1286-93.
28	Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients. Int J Mol Cell Med. 2016;5(1):1-7.
29	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 2019 Oct;19(5):473-479.
30	Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016 Aug;82(2):399-411.
31	SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One. 2012;7(12):e51771.
32	Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy. Pharmacogenet Genomics. 2023 Apr 01;33(3):51-58.
33	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J. 2019 Aug;19(4):390-400.
34	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J. 2020 Dec;20(6):845-856.
35	Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. Pharmacol Res. 2018 May;131:244-254.
36	Genetic Variants of. Genes (Basel). 2025 Jan 24;16(2).
37	Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes. Res Pharm Sci. 2023 Dec;18(6):614-625.
38	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J. 2014 Aug;14(4):328-35.
39	Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor. Pharmacogenomics. 2023 May;24(7):425-434.
40	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. Cancer Chemother Pharmacol. 2017 Apr;79(4):767-773.
41	Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018 May 22;18(3):460-466.
42	The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget. 2017 Oct 20;8(50):88021-88033.
43	Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. Pharmacogenomics. 2020 Apr;21(6):393-402.
44	The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011 Dec;21(12):837-50.
45	The Role of SLC22A1 and Genomic Ancestry on Toxicity during Treatment in Children with Acute Lymphoblastic Leukemia of the Amazon Region. Genes (Basel). 2022 Mar 29;13(4).
46	A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013 Oct;23(10):526-34.
47	The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients.
48	Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide. Int J Mol Sci. 2023 Oct 17;24(20).
49	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed Pharmacother. 2021 Jan;133:111087.
50	Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1. Forensic Sci Int Genet. 2025 Mar;76:103218.
51	Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1). J Pers Med. 2018 Dec 11;8(4).
52	Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1. Front Pharmacol. 2021;12:661480.
53	Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010 Jan;20(1):38-44.
54	Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009 Aug;9(4):242-7.
55	OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82.
56	Association of SLC22A1 rs622342 and ATM rs11212617 polymorphisms with metformin efficacy in patients with type 2 diabetes. Pharmacogenet Genomics. 2022 Feb 01;32(2):67-71.
57	Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration. Pharmacogenomics J. 2024 Oct 07;24(6):31.
58	Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 2015 Nov;15(4):511-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Genetic Polymorphisms

Visitor Map

Correspondence